Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
Not yet recruitingOBSERVATIONAL
Enrollment
10
Participants
Timeline
Start Date
August 31, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
August 31, 2027
Conditions
HER2-positive Breast Cancer
Trial Locations (1)
20132
IRCCS San Raffaele Hospital, Milan
All Listed Sponsors
lead
Giampaolo Bianchini
OTHER
NCT06518382 - Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients | Biotech Hunter | Biotech Hunter